{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:52Z","timestamp":1792320412913,"version":"4.4.0"},"reference-count":86,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Recreational use of piperazine designer drugs is a serious threat to human health. These compounds act on the body in a similar fashion to illegal drugs. They induce psychostimulatory effects as well as visual and auditory hallucinations to varying degrees. In many cases of poisoning and deaths, the presence of two or even several psychoactive substances have been demonstrated. Piperazine derivatives are often found in such mixtures and pose a great analytical problem during their identification. Additionally, some piperazine derivatives can be detected in biological material as a result of metabolic changes to related drugs. Therefore, it is necessary to correctly identify these compounds and ensure repeatability of determinations. This article presents a comparison of the methods used to detect abused piperazine designer drugs using liquid chromatography in combination with a diode-array detector (LC-DAD) or mass spectrometer (LC-MS). Each of methods can be used independently for determinations, obtaining reliable results in a short time of analysis. These methods can also complement each other, providing qualitative and quantitative confirmation of results. The proposed methods provide analytical confirmation of poisoning and may be helpful in toxicological diagnostics.<\/jats:p>","DOI":"10.3390\/jcm11071758","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T23:30:23Z","timestamp":1647991823000},"page":"1758","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4653-3497","authenticated-orcid":false,"given":"Anna","family":"Welz","sequence":"first","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-1443","authenticated-orcid":false,"given":"Marcin","family":"Koba","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-117X","authenticated-orcid":false,"given":"Piotr","family":"Ko\u015bli\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Si\u00f3dmiak","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14756366.2017.1333987","article-title":"Advances in new psychoactive substances identification: The U.R.I.To.N. Consortium","volume":"32","author":"Bertol","year":"2017","journal-title":"Enzym. J. Inhib. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2045125320967197","DOI":"10.1177\/2045125320967197","article-title":"New psychoactive substances: A review and updates","volume":"10","author":"Shafi","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vaiano, F., Bertol, E., Mineo, M., Pietrosemoli, L., Rubicondo, J., Supuran, C.T., and Carta, F. (2021). Development of a New LC-MS\/MS Screening Method for Detection of 120 NPS and 43 Drugs in Blood. Separations, 8.","DOI":"10.3390\/separations8110221"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: Mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Giorgetti, A., Pascali, J.P., Fais, P., Pelletti, G., Gabbin, A., Franchetti, G., Cecchetto, G., and Viel, G. (2021). Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications. Life, 11.","DOI":"10.3390\/life11050440"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Var\u00ec, M.R., Mannocchi, G., Tittarelli, R., Campanozzi, L.L., Nittari, G., Feola, A., Ronchi, F.U., and Ricci, G. (2020). New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17228704"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wadsworth, E., Drummond, C., and Deluca, P. (2018). The Dynamic Environment of Crypto Markets: The Lifespan of New Psychoactive Substances (NPS) and Vendors Selling NPS. Brain Sci., 8.","DOI":"10.3390\/brainsci8030046"},{"key":"ref_8","first-page":"1","article-title":"The Growing Problem of New Psychoactive Substances (NPS)","volume":"32","author":"Madras","year":"2017","journal-title":"Neuropharmacology of New Psychoactive Substances (NPS)"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2174\/138920007781368908","article-title":"N-dealkylation of arylpiperazine derivatives: Disposition and metabolism of the 1-aryl-piperazines formed","volume":"8","author":"Caccia","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.drugalcdep.2011.10.007","article-title":"Piperazine compounds as drugs of abuse","volume":"122","author":"Arbo","year":"2012","journal-title":"Drug Alcohol Dep."},{"key":"ref_11","first-page":"50","article-title":"Toxicology and management of novel psychoactive drugs","volume":"28","author":"Kersten","year":"2015","journal-title":"J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/THC-199008","article-title":"A novel analytical method of TFMPP and mCPP in fluids of drug addicts using LLE-GC\/NPD","volume":"27","author":"Ren","year":"2019","journal-title":"Technol. Health Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugpo.2010.12.002","article-title":"BZP-party pills: A review of research on benzylpiperazine as a recreational drug","volume":"22","author":"Cohen","year":"2011","journal-title":"Int. J. Drug Policy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00204-016-1777-9","article-title":"In vitro hepatotoxicity of \u2018Legal X\u2019: The combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis","volume":"91","author":"Silva","year":"2017","journal-title":"Arch. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00216-012-6548-8","article-title":"Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS\/MS analysis","volume":"405","author":"Swortwood","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/dta.306","article-title":"Development of a rapid LC-MS\/MSmethod for direct urinalysis of designer drugs","volume":"3","author":"Bell","year":"2011","journal-title":"Drug Test. Anal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/15563650.2011.572076","article-title":"The clinical toxicology of the designer \u201cparty pills\u201d benzylpiperazine and trifluoromethylphenylpiperazine","volume":"49","author":"Schep","year":"2011","journal-title":"Clin. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jms.556","article-title":"New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): Studies on its metabolism and toxicological detection in rat urine using gas chromatography\/mass spectrometry","volume":"39","author":"Staack","year":"2004","journal-title":"J. Mass Spectrom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2478\/acph-2020-0035","article-title":"Piperazine derivatives as dangerous abused compounds","volume":"70","author":"Welz","year":"2020","journal-title":"Acta Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0269881118780613","article-title":"Impure but not inactive: Behavioral pharmacology of dibenzylpiperazine, a common by-product of benzylpiperazine synthesis","volume":"32","author":"Dolan","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2017.10.022","article-title":"Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?","volume":"182","author":"Hondebrink","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Welz, A., Koba, M., Ko\u015bli\u0144ski, P., and Si\u00f3dmiak, J. (2021). Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245813"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fpsyt.2017.00240","article-title":"The \u201cEndless Trip\u201d among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review","volume":"8","author":"Orsolini","year":"2017","journal-title":"Front. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2016.04.010","article-title":"Benzylpiperazine: \u201cA messy drug\u201d","volume":"164","author":"Katz","year":"2016","journal-title":"Drug Alcohol Dep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/jat\/bkx090","article-title":"Stability of Synthetic Piperazines in Human Whole Blood","volume":"42","author":"Lau","year":"2018","journal-title":"J. Anal. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/dta.307","article-title":"Current awareness of piperazines: Pharmacology and toxicology","volume":"3","author":"Elliott","year":"2011","journal-title":"Drug Test. Anal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7861\/clinmedicine.14-4-409","article-title":"\u2018Designer drugs\u2019: Update on the management of novel psychoactive substance misuse in the acute care setting","volume":"14","author":"Smith","year":"2014","journal-title":"Clin. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bcp.2014.01.024","article-title":"Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives","volume":"88","author":"Simmler","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF03161209","article-title":"Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) and 1-Benzylpiperazine (BZP)","volume":"4","author":"Wood","year":"2008","journal-title":"J. Med. Toxicol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/00498250310001644544","article-title":"In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step","volume":"34","author":"Staack","year":"2004","journal-title":"Xenobiotica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1107\/S2056989020002844","article-title":"Crystal structures of the recreational drug N-(4-meth\u00acoxy\u00acphen\u00acyl)piperazine (MeOPP) and three of its salts","volume":"76","author":"Kumar","year":"2020","journal-title":"Acta Crystallogr. Crystallogr. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/phar.1424","article-title":"\u201cNot for Human Consumption\u201d: A Review of Emerging Designer Drugs","volume":"34","author":"Musselman","year":"2014","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1440-1797.2011.01537.x","article-title":"Nephrotoxicity of recreational party drugs","volume":"17","author":"Putt","year":"2012","journal-title":"Nephrology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pharma.2008.04.001","article-title":"1-benzylpiperazine (BZP) and 1-(3 trifluoromethylphenyl)piperazine (TFMPP): Emergence of two agents which lead to misuse","volume":"66","author":"Lecompte","year":"2008","journal-title":"Ann. Pharm. Fr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(01)00146-6","article-title":"The subjective effects of MDMA and mCPP in moderate MDMA users","volume":"65","author":"Tancer","year":"2001","journal-title":"Drug Alcohol Dep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ijnp\/pyy047","article-title":"Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics","volume":"21","author":"Luethi","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_37","first-page":"263","article-title":"A Fatality Following Ingestion of the Designer Drug Meta-Chlorophenylpiperazine (mCPP) in an Asthmatic\u2014HPLC-MS\/MS Detection in Biofluids and Hair","volume":"58","author":"Gaillard","year":"2013","journal-title":"J. For. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00213-015-4165-x","article-title":"Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: A single-dose study","volume":"233","author":"Lee","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jchromb.2003.10.004","article-title":"Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry","volume":"798","author":"Staack","year":"2003","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_40","first-page":"487","article-title":"Piperazine derivatives in designer drugs\u2014Compounds of great popularity and high risk for human health","volume":"73","author":"Welz","year":"2017","journal-title":"Farm. Pol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejfs.2014.03.002","article-title":"Development of a targeted GC\/MS screening method and validation of an HPLC\/DAD quantification method for piperazines-amphetamines mixtures in seized material","volume":"4","author":"Boumrah","year":"2014","journal-title":"Egypt. J. Forensic Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.toxlet.2014.06.031","article-title":"Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment","volume":"229","author":"Arbo","year":"2014","journal-title":"Toxicol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yjmcc.2019.09.007","article-title":"Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings","volume":"136","author":"Zwartsen","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.tiv.2015.04.001","article-title":"Hepatotoxicity of piperazine designer drugs: Comparison of different in vitro models","volume":"29","author":"Arbo","year":"2015","journal-title":"Toxicol. Vitr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12640-016-9604-x","article-title":"An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse","volume":"29","author":"Persona","year":"2016","journal-title":"Neurotox. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuro.2018.03.007","article-title":"Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA)","volume":"66","author":"Zwartsen","year":"2018","journal-title":"Neurotoxicology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.toxlet.2012.09.014","article-title":"Estrogenic effects and their action mechanism of the major active components of party pill drugs","volume":"214","author":"Min","year":"2012","journal-title":"Toxicol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/BF00558281","article-title":"Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts","volume":"6","author":"Campbell","year":"1973","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1178646919873925","DOI":"10.1177\/1178646919873925","article-title":"Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions","volume":"12","author":"Scotton","year":"2019","journal-title":"Int. J. Tryptophan Res."},{"key":"ref_50","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2021). European Drug Report: Trends and Developments, Publications Office of the European Union. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/13838\/TDAT21001ENN.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109408","DOI":"10.1016\/j.biopha.2019.109408","article-title":"Review of antidepressants in clinic and active ingredients of traditional Chinese medicine targeting 5-HT1A receptors","volume":"120","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cem.2782","article-title":"Comparison of MLR, OPLS, and SVM as potent chemometric techniques used to estimate in vitro metabolic stability","volume":"30","author":"Ulenberg","year":"2016","journal-title":"J. Chemom."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.2042-7158.1985.tb04940.x","article-title":"In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine","volume":"37","author":"Caccia","year":"1985","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Encinar, J.A., and Menendez, J.A. (2020). Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2\u2032-O-Methylation of Viral RNA. Viruses, 12.","DOI":"10.3390\/v12050525"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.32383\/farmpol\/124913","article-title":"Coronavirus\u2014Current medical and social problem","volume":"76","author":"Welz","year":"2020","journal-title":"Farm. Pol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.4.5935.16","article-title":"Controlled clinical trial of mepiprazole in irritable bowel syndrome","volume":"4","author":"Dotevall","year":"1974","journal-title":"Br. Med. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00325481.2017.1249265","article-title":"A review of trazodone use in psychiatric and medical conditions","volume":"129","author":"Khouzam","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.12659\/AJCR.919833","article-title":"Arrhythmias in Severe Trazodone Overdose","volume":"20","author":"Soe","year":"2019","journal-title":"Am. J. Case Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/WNF.0000000000000235","article-title":"Fatal Cerebral Edema, Seizures, and Hyponatremia after Trazodone Overdose","volume":"40","author":"Avila","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1179\/acb.2001.038","article-title":"Fatal overdose with trazodone: Case report and literature review","volume":"56","author":"Carbutti","year":"2001","journal-title":"Acta Clin. Belg."},{"key":"ref_61","first-page":"131","article-title":"Determination of trazodone and its metabolite 1-(3- chlorophenyl)piperazine (mCPP) in hair by the high performance liquid chromatography method coupled with mass spectrometry (HPLC-ESI-MS)","volume":"66","author":"Stanaszek","year":"2006","journal-title":"Probl. Forensic Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jat\/34.9.587","article-title":"Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT\u00aeII ecstasy immunoassay in urine","volume":"34","author":"Logan","year":"2010","journal-title":"J. Anal. Toxicol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004850-199510030-00002","article-title":"Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine","volume":"10","author":"Ishida","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jat\/27.8.560","article-title":"Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone","volume":"27","author":"Staack","year":"2003","journal-title":"J. Anal. Toxicol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12325-010-0039-0","article-title":"Urapidil, a dual-acting antihypertensive agent: Current usage considerations","volume":"27","author":"Buch","year":"2010","journal-title":"Adv. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2174\/138920009790711823","article-title":"Metabolomics in drug intolerance","volume":"10","author":"Andreu","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0168-8278(92)90027-M","article-title":"Fipexide-induced fulminant hepatitis. Report of three cases with emergency liver transplantation","volume":"15","author":"Durand","year":"1992","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/rcm.3092","article-title":"Investigating the in vitro metabolism of fipexide: Characterization of reactive metabolites using liquid chromatography\/mass spectrometry","volume":"21","author":"Sleno","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_69","first-page":"114","article-title":"Surveillance of emerging drugs of abuse in Hong Kong: Validation of an analytical tool","volume":"21","author":"Tang","year":"2015","journal-title":"Hong Kong Med. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12024-019-00209-z","article-title":"Detection and quantification of synthetic cathinones and selected piperazines in hair by LC-MS\/MS","volume":"16","author":"Niebel","year":"2020","journal-title":"Forensic Sci. Med. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11419-012-0156-3","article-title":"Cross-reactivities of 41 new amphetamine designer drugs to EMIT immunoassays","volume":"31","author":"Nieddu","year":"2013","journal-title":"Forensic. Toxicol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11419-013-0198-1","article-title":"Cross-reactivities of 39 new amphetamine designer drugs on three abuse drugs urinary screening tests","volume":"32","author":"Nieddu","year":"2014","journal-title":"Forensic. Toxicol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00216-009-3394-4","article-title":"LC-MS\/MS screening method for designer amphetamines, tryptamines, and piperazines in serum","volume":"396","author":"Wohlfarth","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chroma.2015.04.002","article-title":"Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching","volume":"1397","author":"Concheiro","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1007\/s00216-014-7825-5","article-title":"Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach","volume":"406","author":"Paul","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jms.3115","article-title":"Screening of methylenedioxyamphetamine and piperazine-derived designer drugs in urine by LC\u2013MS\/MS using neutral loss and precursor ion scan","volume":"48","author":"Montesano","year":"2013","journal-title":"J. Mass Spectrom."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jat\/34.8.464","article-title":"Detection of 1- Benzylpiperazine, 1-(3-Trifluoromethylphenyl)-piperazine, and 1-(3-Chlorophenyl)-piperazine in 3,4-Methylenedioxymethamphetamine-Positive Urine Samples","volume":"34","author":"Dickson","year":"2010","journal-title":"J. Anal. Toxicol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/rcm.6969","article-title":"An analytical approach to the forensic identification of different classes of new psychoactive substances (NPSs) in seized materials","volume":"28","author":"Odoardi","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1515\/CCLM.2004.250","article-title":"Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and\/or doping control","volume":"42","author":"Maurer","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Scientific Working Group for Forensic Toxicology (SWGTOX) (2013). Standard Practices for Method Validation in Forensic Toxicology. J. Anal. Toxicol., 37, 452\u2013474.","DOI":"10.1093\/jat\/bkt054"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1016\/j.jchromb.2009.08.019","article-title":"Internal standard response variations during incurred sample analysis by LC\u2013MS\/MS: Case by case trouble shooting","volume":"877","author":"Tan","year":"2009","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/rcm.895","article-title":"Quantitative characterization of differential ion suppression on liquid chromatography\/atmospheric pressure ionization mass spectrometric bioanalytical methods","volume":"17","author":"Avery","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/rcm.1790","article-title":"Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography\/mass spectrometry: Necessity or not?","volume":"19","author":"Stokvis","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchromb.2005.11.009","article-title":"Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis","volume":"830","author":"Matuszewski","year":"2006","journal-title":"J. Chromatogr. B."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4155\/bio-2017-0059","article-title":"Matrix effect management in liquid chromatography mass spectrometry: The internal standard normalized matrix effect","volume":"9","year":"2017","journal-title":"Bioanalysis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0379-0738(01)00452-2","article-title":"Piperazine-like compounds: A new group of designer drugs-of-abuse on the European market","volume":"121","author":"Bosman","year":"2001","journal-title":"Forensic Sci. Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1758\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:40:54Z","timestamp":1760136054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":86,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11071758"],"URL":"https:\/\/doi.org\/10.3390\/jcm11071758","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]}}}